Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Randomized clinical study Clear all
Completed Phase 1 Interventional

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

NCT07226778
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

NCT03275285
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, carfilzomib, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
San Francisco, California • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

NCT01179217
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle ß0-Thalassemia
Interventions
L-glutamine, Placebo
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Mobile, Alabama • Phoenix, Arizona • Inglewood, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

NCT01147640
View directory record Official record
Conditions
Complicated Intra-abdominal Infection
Interventions
CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Orange, California • Torrance, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

NCT01571297
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Dothan, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

NCT05772520
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TLL018 tablets
Drug
Lead sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Recruiting Phase 3 Interventional

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

NCT07339423
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
22
States / cities
Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Effects of Creatine Supplementation in Breast Cancer Survivors

NCT04207359
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Effect, Muscle Weakness, Muscle Loss, Exercise
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 8, 2026, 4:36 PM EDT
Recruiting Phase 2 Interventional

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

NCT07639359
View directory record Official record
Conditions
Critical Illness, Depressive Symptoms
Interventions
Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
Drug · Other
Lead sponsor
Hospital Italiano de Buenos Aires
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

NCT06687980
View directory record Official record
Conditions
Lichen Simplex Chronicus
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Anaheim, California • Fremont, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Terminated Phase 2 Interventional Results available

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

NCT02162979
View directory record Official record
Conditions
Parkinson's Disease
Interventions
sildenafil, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 8, 2026, 4:36 PM EDT
Recruiting Not applicable Interventional

Balloon Inflation Time for Esophageal Strictures (BITES): A Randomized Multi-Center Study

NCT07100379
View directory record Official record
Conditions
Esophageal Atresia With Tracheo-esophageal Fistula, Esophageal Atresia, Esophageal Strictures
Interventions
Endoscopic Balloon Dilation
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

NCT03106779
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Asciminib, Bosutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
10
States / cities
Chicago, Illinois • Beech Grove, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

NCT00666796
View directory record Official record
Conditions
Insomnia
Interventions
Placebo ethanol, Ethanol, Placebo, Gabapentin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Gentamicin Intravesical Efficacy for Infection of Urinary Tract

NCT04246996
View directory record Official record
Conditions
Postoperative Urinary Tract Infection, Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
gentamicin sulfate, Catheter clamping only
Drug · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

NCT00487188
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Highly active antiretroviral treatment (HAART)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Cleveland, Ohio • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 8, 2026, 4:36 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
WIN378, Placebo
Drug
Lead sponsor
Windward Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

NCT00136903
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

IS-002 Phase 2 Prostate Cancer Study

NCT05946603
View directory record Official record
Conditions
Prostate Cancer
Interventions
Administration of IS-002, Firefly fluorescent imaging, robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
Drug · Device · Procedure
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 8, 2026, 4:36 PM EDT
Recruiting Not applicable Interventional

POEM-F for Achalasia International Study

NCT06042127
View directory record Official record
Conditions
Achalasia
Interventions
POEM-F, Conventional POEM
Procedure
Lead sponsor
Chinese University of Hong Kong
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

NCT00441727
View directory record Official record
Conditions
Gastric Ulcer, Duodenal Ulcer
Interventions
Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 8, 2026, 4:36 PM EDT
Recruiting Not applicable Interventional

Provider Recommendation and HPV Vaccination

NCT05365048
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Local Tailoring implementation strategy, Prescribed Strategy
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years to 70 Years
Enrollment
301,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 8, 2026, 4:36 PM EDT